Development and characterization of a reliable mouse model of colorectal cancer metastasis to the liver

American Cancer Society (2012) Cancer facts and figures 2012. American Cancer Society, Atlanta, pp 25–26 Schima W, Kulinna C, Langenberger H et al (2005) Liver metastases of colorectal cancer: US, CT or MR? Cancer imaging 5 Spec No A:S149–S156 Shibue T, Weinberg RA (2011) Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Semin Cancer Biol 21(2):99–106 Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127(4):679–695 Kaplan RN, Rafii S, Lyden D (2006) Preparing the “soil”: the premetastatic niche. Cancer Res 66(23):11089–11093 Taketo MM, Edelmann W (2009) Mouse models of colon cancer. Gastroenterology 136(3):780–798 Kobaek-Larsen M, Thorup I, Diederichsen A et al (2000) Review of colorectal cancer and its metastases in rodent models: comparative aspects with those in humans. Comp Med 50(1):16–26 Heijstek MW, Kranenburg O (2005) Borel Rinkes IH. Mouse models of colorectal cancer and liver metastases. Digestive surgery 22(1–2):16–25 Alencar H, King R, Funovics M et al (2005) A novel mouse model for segmental orthotopic colon cancer. Int J cancer 117(3):335–339 Cespedes MV, Espina C, Garcia-Cabezas MA et al (2007) Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 170(3):1077–1085 Hackl C, Man S, Francia G et al (2013) Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 62(2):259–271 Bresalier RS, Hujanen ES, Raper SE et al (1987) An animal model for colon cancer metastasis: establishment and characterization of murine cell lines with enhanced liver-metastasizing ability. Cancer Res 47(5):1398–1406 Lin JC, Cheng JY, Tzeng CC et al (1991) An animal model for colon cancer metastatic cell line with enhanced metastasizing ability. Establishment and characterization. Dis Colon Rectum 34(6):458–463 Morikawa K, Walker SM, Nakajima M et al (1988) Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48(23):6863–6871 Morikawa K, Walker SM, Jessup JM et al (1988) In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 48(7):1943–1948 Ijichi H, Chytil A, Gorska AE et al (2011) Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Investig 121(10):4106–4117 Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420–1428 Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9(4):265–273 van Kempen LC, Coussens LM (2002) MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2(4):251–252 Hiratsuka S, Watanabe A, Sakurai Y et al (2008) The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 10(11):1349–1355 Loges S, Mazzone M, Hohensinner P et al (2009) Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15(3):167–170 McAllister SS, Gifford AM, Greiner AL et al (2008) Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 133(6):994–1005 Ichikawa M, Williams R, Wang L et al (2011) S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 9(2):133–148 Kaplan RN, Psaila B, Lyden D (2006) Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond. Cancer Metastasis Rev 25(4):521–529 Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069):820–827 Yamada Y, Yamaguchi T, Matsumoto H et al (2011) Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Invest New Drugs 30(4):1690–1696. doi:10.1007/s10637-011-9743-0 Erler JT, Bennewith KL, Cox TR et al (2009) Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15(1):35–44 Spano D, Zollo M (2012) Tumor microenvironment: a main actor in the metastasis process. Clin Exp Metastasis 29(4):381–395 Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3(6):453–458 Bos PD, Nguyen DX, Massague J (2010) Modeling metastasis in the mouse. Curr Opin Pharmacol 10(5):571–577 Hiratsuka S, Watanabe A, Aburatani H et al (2006) Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8(12):1369–1375 Sun FX, Sasson AR, Jiang P et al (1999) An ultra-metastatic model of human colon cancer in nude mice. Clin Exp Metastasis 17(1):41–48 Thalheimer A, Illert B, Bueter M et al (2006) Feasibility and limits of an orthotopic human colon cancer model in nude mice. Comp Med 56(2):105–109 Rashidi B, Sun FX, Jiang P et al (2000) A nude mouse model of massive liver and lymph node metastasis of human colon cancer. Anticancer res 20(2A):715–722 Rashidi B, Gamagami R, Sasson A et al (2000) An orthotopic mouse model of remetastasis of human colon cancer liver metastasis. Clin cancer res 6(6):2556–2561 Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674 Partin AW, Schoeniger JS, Mohler JL et al (1989) Fourier analysis of cell motility: correlation of motility with metastatic potential. Proc Natl Acad Sci U S A 86(4):1254–1258 Silletti S, Paku S, Raz A (1998) Autocrine motility factor and the extracellular matrix. II. Degradation or remodeling of substratum components directs the motile response of tumor cells. Int J Cancer 76(1):129–135 Malkas LH, Herbert BS, Abdel-Aziz W et al (2006) A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proc Natl Acad Sci U S A 103(51):19472–19477 Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25(1):9–34 Huber MA, Maier HJ, Alacakaptan M et al (2010) BI 5700, a selective chemical inhibitor of IkappaB Kinase 2, specifically suppresses epithelial-mesenchymal transition and metastasis in mouse models of tumor progression. Genes Cancer 1(2):101–114 Otte JM, Schmitz F, Kiehne K et al (2000) Functional expression of HGF and its receptor in human colorectal cancer. Digestion 61(4):237–246 Kammula US, Kuntz EJ, Francone TD et al (2007) Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 248(2):219–228 Grivennikov SI, Karin M (2011) Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 70(Suppl 1):i104–i108 Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9(5):361–371 Bromberg JF, Wrzeszczynska MH, Devgan G et al (1999) Stat3 as an oncogene. Cell 98(3):295–303 Naugler WE, Karin M (2008) The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14(3):109–119 Grivennikov S, Karin E, Terzic J et al (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15(2):103–113 Grivennikov SI, Kuprash DV, Liu ZG et al (2006) Intracellular signals and events activated by cytokines of the tumor necrosis factor superfamily: from simple paradigms to complex mechanisms. Int Rev Cytol 252:129–161 Matthews CP, Colburn NH, Young MR (2007) AP-1 a target for cancer prevention. Curr Cancer Drug Targets 7(4):317–324 Popivanova BK, Kitamura K, Wu Y et al (2008) Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Investig 118(2):560–570 Zaidi MR, Merlino G (2011) The two faces of interferon-gamma in cancer. Clin cancer res 17(19):6118–6124 Gorbacheva VY, Lindner D, Sen GC et al (2002) The interferon (IFN)-induced GTPase, mGBP-2. Role in IFN-gamma-induced murine fibroblast proliferation. J Biol Chem 277(8):6080–6087 Lollini PL, Bosco MC, Cavallo F et al (1993) Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int J cancer 55(2):320–329 Metcalf D, Begley CG, Johnson GR et al (1986) Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 67(1):37–45 Smith BR (1990) Regulation of hematopoiesis. Yale J Biol Med 63(5):371–380 Urdinguio RG, Fernandez AF, Moncada-Pazos A et al (2013) Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors. Cancer Res 73(1):395–405 Scapini P, Morini M, Tecchio C et al (2004) CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol 172(8):5034–5040 Acharyya S, Oskarsson T, Vanharanta S et al (2012) A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150(1):165–178 Berencsi K, Meropol NJ, Hoffman JP et al (2007) Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture. Cancer immunol Immunother 56(3):359–370 Elkabets M, Gifford AM, Scheel C et al (2011) Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Investig 121(2):784–799 Erler JT, Bennewith KL, Nicolau M et al (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440(7088):1222–1226 Erler JT, Giaccia AJ (2006) Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res 66(21):10238–10241